CRS

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Retrieved on: 
Monday, February 26, 2024

“These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors.

Key Points: 
  • “These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors.
  • JANX007 is in a Phase 1a clinical trial in subjects with advanced or metastatic prostate cancer (mCRPC).
  • As of February 12, 2024, 23 subjects were treated with JANX007 in the dose escalation portion of the Phase 1a clinical trial.
  • Based on this safety profile, we are continuing in the dose escalation and optimization portion of the trial for JANX008.

Dominari Securities LLC Continues to Add Depth with Three New Hires

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 7, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has further expanded its practice to include the high-producing private equity investment banking team of Larry Cohen and John Russo and senior manager and director Michael Siek. The three executives join Dominari Securities from AegisStern Ventures.

Key Points: 
  • Mr. Cohen and Mr. Russo will each serve as Managing Director, Private Equity & Capital Markets at Dominari Securities.
  • Mr. Kyle Wool, CEO of Dominari Securities LLC, commented, "We are absolutely committed to positioning Dominari as a full-service, diversified financial services firm with a deep bench of credentialed financial experts.
  • Securities Brokerage and Registered Investment Adviser Services are offered through Dominari Securities LLC, a Member of FINRA, MSRB and SIPC.
  • Information for Dominari Securities LLC and its registered investment professionals as well as its SEC Form CRS may also be found on FINRA's BrokerCheck site.

Dominari Securities LLC Welcomes Wealth Management Team Gotham Equities

Retrieved on: 
Wednesday, March 6, 2024

NEW YORK, March 6, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has expanded its wealth management team to include Mr. David Reimer, CEO of Gotham Equities; Wealth Advisor, Mr. Peter Sandler, and a team of five experienced wealth management professionals from Gotham Equities.

Key Points: 
  • NEW YORK, March 6, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has expanded its wealth management team to include Mr. David Reimer, CEO of Gotham Equities; Wealth Advisor, Mr. Peter Sandler, and a team of five experienced wealth management professionals from Gotham Equities.
  • Mr. Kyle Wool, CEO of Dominari Securities LLC, commented, "Adding Peter and this accomplished team of wealth management advisors significantly strengthens our bench and provides us with additional depth to support the growth of our business.
  • Prior to joining Dominari, he served as Senior Partner at Gotham Equities, where he worked with a select group of individuals, families and institutions, offering comprehensive wealth management services, including retirement planning, investment management, estate and trust planning and insurance.
  • Securities Brokerage and Registered Investment Adviser Services are offered through Dominari Securities LLC, a Member of FINRA, MSRB and SIPC.

Dominari Securities LLC Welcomes Another Wealth Management Team

Retrieved on: 
Tuesday, March 5, 2024

NEW YORK, March 5, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has further expanded its wealth management practice to include a team of 12 seasoned wealth advisors led by Mr. Michael Schiavello and Mr. Billy Takos. 

Key Points: 
  • Adds seasoned Wealth Advisors, Michael Schiavello and Billy Takos, and team of 12 experienced wealth advisors
    NEW YORK, March 5, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has further expanded its wealth management practice to include a team of 12 seasoned wealth advisors led by Mr. Michael Schiavello and Mr. Billy Takos.
  • "The addition of these wealth management advisors is the second team in as many weeks to join Dominari Securities.
  • Securities Brokerage and Registered Investment Adviser Services are offered through Dominari Securities LLC, a Member of FINRA, MSRB and SIPC.
  • Information for Dominari Securities LLC and its registered investment professionals as well as its SEC Form CRS may also be found on FINRA's BrokerCheck site.

RRC's 36th Sell-a-bration®: Uniting and Advancing the Best in Real Estate

Retrieved on: 
Thursday, February 29, 2024

LAS VEGAS, Feb. 29, 2024 /PRNewswire/ -- The Residential Real Estate Council's (RRC) Sell-a-bration®, now in its 36th year, promises a transformative experience for hundreds of top-producing real estate agents.

Key Points: 
  • LAS VEGAS, Feb. 29, 2024 /PRNewswire/ -- The Residential Real Estate Council's (RRC) Sell-a-bration®, now in its 36th year, promises a transformative experience for hundreds of top-producing real estate agents.
  • Learn from the best: This year's Sell-a-bration features an enriching lineup of 28 education sessions spread across two days.
  • Celebrate achievements: Witness the inaugural CRS Commencement, where over 40 new CRS Designees are recognized for their dedication and accomplishments in the field joining "the best of the best."
  • "Sell-a-bration offers a unique and comprehensive platform for real estate professionals to thrive," says Tricia Nekota, 2024 RRC President.

Dominari Securities LLC Welcomes Seasoned Wealth Management Advisor Raymond Guarini

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, is growing its wealth management team with the addition of senior wealth management executive Mr. Raymond Guarini.

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, is growing its wealth management team with the addition of senior wealth management executive Mr. Raymond Guarini.
  • Mr. Kyle Wool, CEO of Dominari Securities LLC, commented, "A principal component of our 'growth and development' strategy is hiring and retaining wealth management professionals who have assets under management.
  • Securities Brokerage and Registered Investment Adviser Services are offered through Dominari Securities LLC, a Member of FINRA, MSRB and SIPC.
  • Information for Dominari Securities LLC and its registered investment professionals as well as its SEC Form CRS may also be found on FINRA's BrokerCheck site.

U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)

Retrieved on: 
Tuesday, February 27, 2024

NORTH CHICAGO, Ill., Feb. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a subcutaneously administered T-cell engaging bispecific antibody for the treatment of adult relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of therapy. If approved, epcoritamab-bysp (EPKINLY®) will be the first and only subcutaneous bispecific antibody to treat adults with R/R FL after two lines of prior therapy, marking its second indication following FDA and European Medicines Agency (EMA) approval of R/R third-line diffuse large B-cell lymphoma (DLBCL) treatment.

Key Points: 
  • The FDA grants Priority Review to investigational therapies that, if approved, may offer significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions when compared to standard applications.
  • This designation shortens the review period to six months compared to 10 months for Standard Review.
  • "Together with our partner Genmab, we are committed to further advancing epcoritamab as a core lymphoma therapy."
  • Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication.

Dominari Securities LLC Serves as Lead Underwriter for $5 Million Initial Public Offering for Unusual Machines

Retrieved on: 
Thursday, February 15, 2024

The shares of Unusual Machines began trading on the NYSE American on February 14, 2024, under the ticker symbol "UMAC".

Key Points: 
  • The shares of Unusual Machines began trading on the NYSE American on February 14, 2024, under the ticker symbol "UMAC".
  • Dominari Securities LLC, Revere Securities LLC, and R.F.
  • Securities Brokerage and Registered Investment Adviser Services are offered through Dominari Securities LLC, a Member of FINRA, MSRB and SIPC.
  • Information for Dominari Securities LLC and its registered investment professionals as well as its SEC Form CRS may also be found on FINRA's BrokerCheck site.

Biofourmis Secures Four New Agreements with Top-20 Pharma on Strength of Platform for Digital Clinical Trials and Digital Biomarkers

Retrieved on: 
Tuesday, February 13, 2024

The new engagements focus on oncology therapies, further expanding Biofourmis' already diverse therapeutic portfolio that includes cardiovascular, pain, women's health, and immunology.

Key Points: 
  • The new engagements focus on oncology therapies, further expanding Biofourmis' already diverse therapeutic portfolio that includes cardiovascular, pain, women's health, and immunology.
  • In addition to digital biomarker and endpoint expertise, pharmaceutical companies are engaging Biofourmis to reduce study timelines by leveraging its Digital Clinical Trials solution following a significant investment in 2023 to expand and optimize its features and performance .
  • To increase participant engagement and ease clinical site burden, Biofourmis also offers a remote clinical care team to help overcome adherence obstacles and perform real-time monitoring.
  • This comprehensive platform and services offering gives researchers the flexibility of running fully decentralized or hybrid clinical trials.

Toyota Boshoku America Signs Long-term Renewable Energy Certificate Agreement

Retrieved on: 
Thursday, February 8, 2024

This is TBA’s first renewable energy procurement at scale in the U.S. and will enable the company to effectively offset 100% of its annual electricity consumption in its U.S. and Canada facilities with renewable energy.

Key Points: 
  • This is TBA’s first renewable energy procurement at scale in the U.S. and will enable the company to effectively offset 100% of its annual electricity consumption in its U.S. and Canada facilities with renewable energy.
  • “TBA is thrilled to reach this agreement with Clearway for renewable energy certificates.
  • “Our collaborative relationship has been pivotal in shaping TBA's renewable energy strategy, underscoring their dedication to fast-tracking sustainable progress.
  • Schneider Electric, the leading advisor on corporate renewable energy procurement globally, supported the Company in the selection of and negotiations for the project.